Literature DB >> 17398154

Cellular cardiomyoplasty in large myocardial infarction: can the beneficial effect be enhanced by ACE-inhibitor therapy?

Emerson L Olivares1, Ricardo H Costa-E-Sousa, João P S Werneck-de-Castro, Vanessa Pinho-Ribeiro, Márcia G Silva, Karla C Ribeiro, Elisabete C Mattos, Regina C S Goldenberg, Antonio C Campos de Carvalho, Masako Oya Masuda.   

Abstract

BACKGROUND: Cellular cardiomyoplasty with bone marrow derived stromal (MSC) and mononuclear (BMNC) cells has been shown to improve performance of infarcted hearts. We performed a comparative study with MSC and BMNC and tested the hypothesis that captopril treatment could enhance the beneficial effect of cell therapy in large myocardial infarctions.
METHODS: Male syngeneic Wistar rats underwent experimental infarction and were randomized to receive 1-3 x 10(6) MSC, 10(8) BMNC or vehicle (BSS group). Two additional groups were treated with captopril and received 1-3 x 10(6) MSC (Cap.MSC) or vehicle (Cap).
RESULTS: The ejection fraction (EF%) of MSC and BMNC-treated rats was higher than in the BSS rats, eight weeks after transplantation (33.0+/-4.0, 34.0+/-2.0 and 20.0+/-2.0% respectively, P<0.01). Both captopril-treated groups improved EF% similarly. But only captopril plus MSC treatment almost restored cardiac function to control levels, 8 weeks after injection (60.50+/-5.40% vs. 41.00+/-4.50% in Cap.MSC and Cap respectively, P<0.05). Many DAPI-labelled cells were found in the scar tissue of the left ventricle only in the Cap.MSC group.
CONCLUSIONS: Cell transplantation with both MSC and BMNC produced a similar stabilisation of heart function, but the success of the cell engraftment and the recovery of cardiac performance were dependent on concomitant treatment with captopril.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17398154     DOI: 10.1016/j.ejheart.2007.02.003

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  6 in total

1.  Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives.

Authors:  C Qian; R G Schoemaker; W H van Gilst; B Yu; A J M Roks
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

2.  Progression of heart failure is attenuated by antioxidant therapy with N-acetylcysteine in myocardial infarcted female rats.

Authors:  César R M Costa; Fernando A C Seara; Milena S Peixoto; Isalira P Ramos; Raiana A Q Barbosa; Adriana B Carvalho; Rodrigo S Fortunato; Anderson L B Silveira; Emerson L Olivares
Journal:  Mol Biol Rep       Date:  2020-10-13       Impact factor: 2.316

3.  Bone marrow mesenchymal cells improve muscle function in a skeletal muscle re-injury model.

Authors:  Bruno M Andrade; Marcelo R Baldanza; Karla C Ribeiro; Anderson Porto; Ramon Peçanha; Fabio S A Fortes; Gisele Zapata-Sudo; Antonio C Campos-de-Carvalho; Regina C S Goldenberg; João Pedro Werneck-de-Castro
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

4.  Propranolol inhibits myocardial infarction-induced brown adipose tissue D2 activation and maintains a low thyroid hormone state in rats.

Authors:  F A C Seara; I G Araujo; G E Império; M P Marassi; A C M Silva; A S Mecawi; L C Reis; E L Olivares
Journal:  Braz J Med Biol Res       Date:  2019-10-10       Impact factor: 2.590

5.  Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study.

Authors:  Carolyn A Carr; Daniel J Stuckey; Louise Tatton; Damian J Tyler; Sarah J M Hale; Dominic Sweeney; Jürgen E Schneider; Enca Martin-Rendon; George K Radda; Sian E Harding; Suzanne M Watt; Kieran Clarke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-06       Impact factor: 4.733

6.  Dynamic Tracking of Injected Mesenchymal Stem Cells after Myocardial Infarction in Rats: A Serial 7T MRI Study.

Authors:  Xiuyu Chen; Minjie Lu; Ning Ma; Gang Yin; Chen Cui; Shihua Zhao
Journal:  Stem Cells Int       Date:  2016-08-30       Impact factor: 5.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.